JCO: Risk of atrial fibrillation and related factors after hematoblast transplantation

Hematoblast transplantation (HCT) is an effective treatment for many blood diseases.
over the past 50 years, improvements in HCT programs have dramatically improved the survival prognostics of many patients.
cardiovascular complications such as myocardial infarction, stroke and heart failure are the leading cause of long-term death in patients with HCT.
study aims to assess the rate and risk factors of new atrial fibrillation (AF) after the heterogeneity HCT, as well as the effects of AF on HCT-related prognosmation.
study was a retrospective, including 487 patients who had heterogeneity HCT between 2014 and 2016.
the patient received HCT with a medium age of 52.4 years (18.1-78.6) and a medium interval of 117.5 days (4.0-405.1) after HCT.
10.6 per cent over the five-year cumulative rate of AF.
independent risk factors for
AF are: older (≥ 50 years old; risk ratio of HR 2.76), HLA unrelevant feed (2.20), blood lipid abnormality (2.40) and HCT pre-QTc interstate extension (2.25).
compared to patients without AF, although the left adipulation function is comparable, but the left cerension blood score of patients with AF, left cerencage reserve function is significantly higher, and the speed of trilocation valve reflow is also faster.
the risk of stroke after the AF was 143/1000.
correction analysis, AF was associated with a 12.8-fold increase in all-cause mortality and a 15.8-fold increase in the risk of non-relapse deaths.
, patients with the heterogeneity HCT have a certain risk burden of developing AF, and once AF occurs, the risk of poor prognosis increases.
some of the factors associated with AF risk revealed in this study may provide guidance for the development of targeted prevention strategies during and after HCT.